Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
| Revenue (TTM) | $9.01M |
| Gross Profit (TTM) | $6.28M |
| EBITDA | $-12.72M |
| Operating Margin | -160.90% |
| Return on Equity | -609.00% |
| Return on Assets | -87.80% |
| Revenue/Share (TTM) | $116.09 |
| Book Value | $-32.20 |
| Price-to-Book | 0.18 |
| Price-to-Sales (TTM) | 0.21 |
| EV/Revenue | 0.0003 |
| EV/EBITDA | -0.34 |
| Quarterly Earnings Growth (YoY) | -99.20% |
| Quarterly Revenue Growth (YoY) | 14.10% |
| Shares Outstanding | 405,250 |
| Float | 383,700 |
| % Insiders | 3.72% |
| % Institutions | 3.19% |
Submission represents a significant regulatory milestone in advancing access to precision fluid management for smaller pediatric patients Submission represents a significant regulatory milestone in advancing access to precision fluid management for smaller pediatric patients
MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 12, 2026, and will host a conference call beginning at 9:00 a.m. Eastern time.
ULTRA-Peds Registry evaluated 91 pediatric patients across seven leading children's hospitals, providing important clinical evidence which the Company intends to use to support its proposed label expansion of Aquadex's indication to patients weighing 5 kg and above ULTRA-Peds Registry evaluated 91 pediatric patients across seven leading children's hospitals, providing important clinical evidence which the Company intends to use to support its proposed label expansion of Aquadex's indication to patients weighing 5 kg and above
MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company's next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform.
MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow® system in providing precise, controlled fluid removal for patients who require individualized fluid management.
Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements
Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development
MINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress under its financial efficiency strategy, including significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure.
Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution
Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NUWE and any ticker you trade — then tracks every position and per-strategy win rate.
